TUCSON,
Ariz., Oct. 24, 2022 /PRNewswire/ -- Accelerate
Diagnostics, Inc. (NASDAQ: AXDX) announced today that management
will host a conference call on Monday,
November 14, 2022, at 4:30 p.m.
Eastern Time to review 2022 third quarter results.
To listen to the audio webcast online, visit ir.axdx.com. A
replay of the audio webcast will be available for 30 days.
To listen by phone, dial +1.877.883.0383 and enter the Elite
Entry Number: 5844198. International participants may dial
+1.412.902.6506. Please dial in 10-15 minutes prior to the start of
the conference.
A replay of the call will be available by telephone at
+1.877.344.7529 (U.S.) or +1.412.317.0088 (International) using the
replay code 7894082 until December 5, 2022.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics
company dedicated to providing solutions for the global challenges
of antimicrobial resistance and sepsis. The Accelerate Pheno®
system is designed to reduce the time clinicians must wait to
determine the most optimal antibiotic therapy for bacteremic
patients. These diagnostic systems are designed to serve clinical
laboratories with automated solutions to expedite time to
identification and antimicrobial susceptibility test (AST) results
directly from positive blood culture samples. Multiple external
studies have proven that Accelerate solutions deliver results 1 to
2 days faster than existing methods, enabling clinicians to
optimize antibiotic selection and dosage specific to the individual
patient's infection, days earlier.
The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and
"ACCELERATE PHENOTEST" and diamond shaped logos and marks are
trademarks or registered trademarks of Accelerate Diagnostics,
Inc.
For more information about the company, its products and
technology, or recent publications, visit axdx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-scheduled-call-to-review-2022-third-quarter-results-301657334.html
SOURCE Accelerate Diagnostics, Inc.